Company Information

    Talaris Therapeutics was founded on January 2002. The company is based in Wellesley, MA, USA . The number of employees in Talaris Therapeutics is less than 50. Talaris therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies.

    Here is how Talaris Therapeutics describes itself: "Talaris seeks to help kidney transplant recipients and patients suffering from severe auto-immune diseases to live healthy lives free from chronic immunosuppression"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Talaris Therapeutics has received 2 rounds of venture funding. The total funding amount is around $215M. Last venture funding round was $115M, announced on October, 2020.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Talaris Therapeutics - Blog

                          • Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer

                          • BOSTON, Mass., and LOUISVILLE, Ky., March 4, 2021 – Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune or metabolic disorders, today announced the appointment of Mary Kay Fenton as Chief […]The post Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer appeared first on Talaris.
                          • Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance

                          • BOSTON, Mass., and LOUISVILLE, Ky., February 25, 2021 – Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune, or metabolic disorders, today announced the […]The post Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance appeared first on Talaris.
                          • Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors

                          • BOSTON, Mass., and LOUISVILLE, Ky., January 20, 2021– Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the appointment of Sapna Srivastava, Ph.D., and Gaurav Shah, M.D., as independent representatives to its Board of Directors. “Sapna and […]The post Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors appeared first on Talaris.
                          • Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

                          • BOSTON, Mass., and LOUISVILLE, Ky., January 8, 2021 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, is scheduled to virtually present at the 39th Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Scott Requadt will present a […]The post Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference appeared first on Talaris.
                          • Talaris Therapeutics Expands Leadership Team with Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations

                          • BOSTON, Mass., and LOUISVILLE, Ky., November 12, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the expansion of its senior leadership team with the appointments of Michael Zdanowski as Chief Technology Officer, Farah Natoli […]The post Talaris Therapeutics Expands Leadership Team with Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations appeared first on Talaris.
                          • Talaris Therapeutics lands $115M in venture capital funding

                          • Louisville Business First: The is the second time in about 18 months that this company has turned heads with its capital raises. FULL STORYThe post Talaris Therapeutics lands $115M in venture capital funding appeared first on Talaris.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *